Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT01816035
Title Ado-Trastuzumab Emtansine in Treating Patients With HER2-Positive Metastatic or Locally Advanced Breast Cancer That Cannot Be Removed by Surgery
Recruitment Completed
Gender both
Phase Phase I
Variant Requirements No
Sponsors University of Washington

Her2-receptor positive breast cancer


Ado-trastuzumab emtansine

Age Groups: adult
Covered Countries USA

No variant requirements are available.